摘要
对1例使用氯吡格雷二级预防,CYP2C19基因检测结果为"氯吡格雷慢代谢",血小板聚集实验结果为"血小板聚集显著被抑制"的脑卒中复发患者为例,分析以上基因检测、血小板聚集实验、脑卒中复发三者的辩证关系,讨论抗血小板的用药选择。氯吡格雷基因检测对脑卒中患者二级预防的效果具有一定指导意义,血小板聚集实验结果不能全面评估体内血小板的生理及功能。一些特殊患者脑卒中二级预防中抗血小板治疗的方案还需进一步探讨和优化,以期寻找更具有安全性、有效性、合理性的抗血小板治疗方案。
A case of recurrent stroke with clopidogrel secondary prevention,CYP2C19 gene testing result of"clopidogrel slow metabolism",platelet aggregation test result of"platelet aggregation significantly inhibited"as an example,the dialectical relationship among the above gene testing,platelet aggregation test,stroke recurrence were analyzed,and the choice of antiplatelet drugs was discussed.Clopidogrel gene testing has certain guiding significance for the secondary prevention of stroke patients.Platelet aggregation test results can not comprehensively evaluate the physiology and function of platelets in vivo.In order to find a more safe,effective and reasonable antiplatelet therapy,antiplatelet therapy should be further explored and optimized.
作者
杨希
李丽
陈頔
杨梦婷
宋江曼
刘燕
Yang Xi;Li Li;Chen Di;Yang Mengting;Song Jiangman;Liu Yan(Department of Pharmacy,The Third People′s Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830000,China;Department of Pharmacy,Beijing Hospital,Beijing 100730,China)
出处
《中国综合临床》
2020年第6期564-567,共4页
Clinical Medicine of China
